Navigation Links
Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development Program
Date:5/12/2009

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that the Company will hold a conference call and webcast to discuss recent developments and future plans for its Excellarate(TM) clinical development program.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

On May 6, 2009, the Company announced the completion of recruitment for the Tissue Repair Company's pioneering gene therapy Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of its Excellarate product candidate for the potential treatment of non-healing foot ulcers in patients with type I or type II diabetes. In addition, on May 7, 2009, Cardium announced significant new formulation enhancements for Excellarate that are designed to simplify and broaden the use of the product candidate for diabetic ulcers, and also expand the potential applicability into a number of additional wound healing market opportunities, including pressure and venous stasis ulcers, as well as major surgical and serious trauma wounds.

Cardium will hold a live conference call and webcast Thursday, May 14, 2009 at 4:30 p.m. (Eastern). Participants can access the live conference call by dialing 866-202-1971(US) or 617-213-8842 (International) using the conference passcode 37347570. The call and accompanying slides can also be accessed via the webcast through the Company's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-calendar.

If you are unable to attend the webcast a replay of the
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), one ... services, offering both facility-based and home-based post-acute services, ... second quarter ended June 30, 2015. ... growth in both segments and an 11.0% increase ... and Chief Executive Officer of HealthSouth. "While reported ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... 2015  Therapath Neuropathology ( www.Therapath.com ), a ... VA and Military Medical centers both domestically and ... and Sweat Gland Nerve Fiber Density (SGNFD) for ... ). Demonstration of a reduction ... punch skin biopsy is a highly sensitive and ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27
... Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today that ... and chief operating officer, effective March 1, 2008., ... of 2007 as executive vice,president and chief operating ... research and development, manufacturing, and,sales and marketing., ...
... be held on Thursday, February 21, 2008 at 5:00 ... (Eastern) / 9:00 pm (Beijing/Hong Kong), SHENYANG, China, ... biotechnology company focused on researching,developing, manufacturing and marketing biopharmaceutical ... for the fourth,quarter and full year ended December 31, ...
... Products,Corp. (OTC Bulletin Board: TKER), a manufacturer and ... today,reported that it has installed its equipment to ... new plant operated by one of the,top 10 ... test of the,application to gauge its effectiveness, during ...
Cached Biology Technology:Carl Hull Named President and Chief Operating Officer of Gen-Probe 2Carl Hull Named President and Chief Operating Officer of Gen-Probe 33SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008 2Tasker Products Installs Scalder Application at New Poultry Processor's Facility 2Tasker Products Installs Scalder Application at New Poultry Processor's Facility 3
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... , 31. Juli 2015 Die 10. internationale Konferenz ... BGI veranstaltet und findet vom 22. bis 25. ... , statt. Die Konferenz feiert ... Start 2006 ist die ICG weltweit zu einem ... Sie ist eines der dynamischsten, enthusiastischsten und angenehmsten ...
(Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... molecular mechanism in the liver that explains, for the ... and trans-fatty acids causes elevated blood levels of cholesterol ... and certain cancers. , In the Jan. 28 issue ... that the harmful effects of saturated and trans fats ...
... treated with radical mastectomy and adjuvant chemotherapy, the addition ... few long-term toxic effects, according to a 20-year follow-up ... 19 issue of the Journal of the National Cancer ... was designed to determine the effect on survival of ...
... a recent U.S. study, investigators in Japan found no ... form of high blood pressure, as reported in the ... now available online. , The researchers reported that they ... also known as the Kaposi's sarcoma virus, in the ...
Cached Biology News:Scientists ID molecular 'switch' in liver that triggers harmful effects of saturated and trans fats 2Scientists ID molecular 'switch' in liver that triggers harmful effects of saturated and trans fats 3Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down 2Association of herpesvirus with lung disorder questioned 2
...
Rubeola (Measles) Antigen Preservative: No Preservatives...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
Biology Products: